SBIR/STTR Research Award
A novel antisense therapeutic for treatment of Aspergillus fumigatus infections
Award amount
$170,092Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- GUILD ASSOCIATES INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- G1RKNNXESY18
- Solicitation number
- PA13-234
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): Guild proposes to develop an antisense oligomer-based antifungal effective against the human pathogen Aspergillus fumigatus. With a 40%-60% mortality rate, invasive aspergillosis (IA) due to A. fumigatus now surpasses invasive candidiasis as the most frequent fungal cause of death, especially amongst immunocompromised patients. Successful therapy for IA with current antifungals is notoriously difficult due to poor clinical efficacy and the increasing emergence of drug resistant strains. Despite this acute need for novel therapeutic strategies, there has not been a new class of antifungals targeting A. fumigatus developed in over 12 years. Therefore, a novel approach is urgently needed to develop new anti-Aspergillus targeting strategies. Phosphorodiamidate morpholino oligomers (PMOs), synthetic uncharged analogs of nucleic acids, are an antisense biotechnology that functions by base pairing with target gene mRNA, producing steric blockade of the translational machiner
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Improved Anerobic Digester Biogas Production through the Application of Immobilized Enzymes
- SBIR PHASE I (NIMH TOPIC 3): POINT-OF-CARE AND PHARMACY-BASED ANTIRETROVIRAL DRUG ADHERENCE ASSAYS - POINT-OF-CARE ANTI-RETROVIRAL DRUG ADHERENCE IMPEDANCE SPECTROSCOPY DEVICE
- NIMH SBIR PHASE I TOPIC 001- POINT-OF-CARE HIV VIRAL LOAD AND DRUG ADHERENCE ASSAYS HIV, pre-exposure prophylaxis, antiretroviral therapy, electrochemistry, impedance spectroscopy, viral load, point of care, sensor
- Immobilization of Enzymes for Enhanced Production of Protein Hydrolysate and Lactose Free Products from Whey
- POINT-OF-CARE ELECTROCHEMICAL APTASENSOR FOR LONG-TERM PHARMACOLOGICAL ADHERENCE MONITORING
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
72 SBIR/STTR records share this UEI (1983–2025). Reported award amounts total $19,817,804. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Defense, Department of Health and Human Services, National Science Foundation, Department of Agriculture, Environmental Protection Agency, Department of Commerce